Ritter Pharmaceuticals’ (RTTR) Buy Rating Reaffirmed at Maxim Group
Ritter Pharmaceuticals Inc (NASDAQ:RTTR)‘s stock had its “buy” rating restated by equities research analysts at Maxim Group in a research report issued on Monday.
Separately, Zacks Investment Research lowered Ritter Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 14th.
Ritter Pharmaceuticals (NASDAQ:RTTR) traded up 10.00% during midday trading on Monday, hitting $1.87. The stock had a trading volume of 25,927 shares. The stock has a 50-day moving average price of $1.55 and a 200 day moving average price of $1.53. Ritter Pharmaceuticals has a one year low of $0.98 and a one year high of $2.63. The firm’s market cap is $16.05 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/ritter-pharmaceuticals-rttr-buy-rating-reaffirmed-at-maxim-group.html
Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its quarterly earnings results on Monday, August 8th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.14. On average, analysts predict that Ritter Pharmaceuticals will post ($1.38) earnings per share for the current year.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.